Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
复制标题
DOI：
10.1093/annonc/mds620
复制
发表时间：
2013-05-01
影响因子：
50.5
通讯作者：
Karayan-Tapon, L.
中科院分区：
文献类型：
--
作者：
Tougeron, D.;Lecomte, T.;Karayan-Tapon, L.
背景资料：只有野生型（WT）KRAS肿瘤患者才能从抗表皮生长因子受体（EGFR）单克隆抗体（Mab）治疗转移性结直肠癌（mCRC）中获益。焦磷酸测序现在广泛用于确定KRAS突变负荷，并且已经定义了10%的保守截止点。到目前为止，低频KRAS突变的影响（
Background: Only patients with wild-type (WT) KRAS tumors benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mabs) in metastatic colorectal cancer (mCRC). Pyrosequencing is now widely used for the determination of KRAS mutation burden and a conservative cut-off point of 10% has been defined. Up until now, the impact of low-frequency KRAS mutations (